International

Data monetisation drives Sanofi’s $180 million investment in AI biotech Owkin

The deal shows how privacy and silo barriers to the commercialisation of information are being overcome

Data monetisation drives Sanofi’s $180 million investment in AI biotech Owkin
The global patent landscape in nine charts
19 Nov 2021

The global patent landscape in nine charts

The top takeaways from WIPO’s latest World Intellectual Property Indicators report

Moderna on IP collision course with US government
11 Nov 2021

Moderna on IP collision course with US government

The company is at loggerheads with National Institutes of Health over inventorship of crucial covid vaccine technology

Latest

View all
5 Nov 2021

A $650 million deal is the latest in a growing number of CRISPR IP transactions

Last week’s licensing agreement between Mammoth and Vertex shows how deal-making in the space is gathering momentum Read more

2 Nov 2021

Key takeaways from Merck’s landmark covid IP licensing deal with the Medicines Patent Pool

The agreement is the first granting non-exclusive and royalty free rights to sub-licensees of a covid therapeutic or vaccine Read more

1 Nov 2021

Flexibility crucial to growing appeal of big money drug royalty transactions, says leading deal-maker

In the wake of the firm’s latest $250 million investment, Sagard Healthcare Royalty Partners’ Ali Alagheband gives the inside track on life sciences IP-backed revenue sales Read more

22 Oct 2021

Hub and spoke IP strategies are generating billions of dollars in biopharma

New Crinetics spin-off is more evidence of the growing influence of models designed to monetise non-core life sciences assets Read more

Designs

View all
20 May 2020

IP Hall of Fame 2020 inductees announced

A UK Supreme Court justice, a former USPTO acting director, a globally-renowned IP scholar, a trailblazing trademark lawyer and a one-time presidential candidate form the class of 2020 Read more

28 Apr 2020

How IP owners have responded to the covid-19 challenge so far

Several innovators have already waived exclusivities, but big decisions for right holders lie ahead Read more

26 Mar 2020

Final call to take part in this year’s IAM benchmarking survey

Help us to identify the key trends currently shaping the global IP market Read more

18 Feb 2020

Tell us what you think of the latest developments in the global IP market

IAM's annual IP benchmarking survey opens today Read more

Finance

View all
29 Jun 2021

University and Big Pharma JV’s $145 million take-off is a big boost for tech transfer dealmaking

Apollo Therapeutics is an innovative biotech formed by three UK universities and three major companies, with a promising model for creating and monetising life sciences IP Read more

18 Feb 2021

Seven top IP tips for biotech SMEs

How smaller biotechs can best overcome pitfalls and maximise the value of their inventions Read more

26 Mar 2020

Final call to take part in this year’s IAM benchmarking survey

Help us to identify the key trends currently shaping the global IP market Read more

18 Mar 2020

Help us map the latest developments in the global IP market

There’s not long left to answer our annual IP benchmarking survey Read more

Frand/SEPS

View all
16 Sep 2021

Apple didn’t want fair FRAND arbitration, Qualcomm VP says of epic litigation battle

Marc Snyder also claims that the iPhone giant helped the FTC craft “bizarre” antitrust claims that were eventually dismissed Read more

26 Mar 2020

Final call to take part in this year’s IAM benchmarking survey

Help us to identify the key trends currently shaping the global IP market Read more

18 Mar 2020

Help us map the latest developments in the global IP market

There’s not long left to answer our annual IP benchmarking survey Read more

28 Feb 2020

The US has a mountain to climb in 5G network equipment

Patent analysis shows that American companies would need to make big plays if they want to catch the Chinese, but it is almost certainly too late already Read more

Law & Policy

View all
15 Oct 2021

Moderna’s covid-19 patent pledge may be backfiring

Though a short-term PR success, the company’s commitment risks looking hollow after its decision not to license know-how to new WHO Africa tech-transfer hub Read more

16 Sep 2021

Apple didn’t want fair FRAND arbitration, Qualcomm VP says of epic litigation battle

Marc Snyder also claims that the iPhone giant helped the FTC craft “bizarre” antitrust claims that were eventually dismissed Read more

17 Jun 2021

Everything you need to know about the covid-19 IP waiver negotiations

With text-based discussions of a TRIPS suspension about to get underway, IAM highlights the key issues to be aware of. Read more

18 May 2021

India resists calls to use existing compulsory licensing powers for covid drugs

Despite advocacy of TRIPS waiver, the country’s government has expressed reluctance to bypass patent rights Read more

Litigation

View all
16 Sep 2021

Apple didn’t want fair FRAND arbitration, Qualcomm VP says of epic litigation battle

Marc Snyder also claims that the iPhone giant helped the FTC craft “bizarre” antitrust claims that were eventually dismissed Read more

9 Sep 2021

Private practice leadership roundtable

Read more

30 Mar 2021

Latest Humira dispute highlights biosimilar trade secrets dangers

As the biologics industry expands, strategies for protecting proprietary and confidential information are becoming ever-more essential Read more

18 Feb 2021

Seven top IP tips for biotech SMEs

How smaller biotechs can best overcome pitfalls and maximise the value of their inventions Read more

Market Developments

View all
9 Sep 2021

Private practice leadership roundtable

Read more

26 Aug 2021

Pfizer’s $2.3 billion spend on CD47 inhibitors shows how oncology IP continues to drive pharma deal-making

The acquisition of the cutting-edge haematology candidates is just the latest development in the booming immuno-oncology market Read more

17 Aug 2021

New study shows surge in data-driven and computer-assisted healthcare patents

Boom in digital healthcare and bioinformatics IP requires strategic adjustments in both the life sciences and high-tech arenas Read more

12 Aug 2021

mRNA IP will be hot property beyond the pandemic

$3.2 billion Sanofi deal is unlikely to be the last as Big Pharma seeks to consolidate its position in the cutting-edge field Read more

Non-Practising Entities

View all
18 Feb 2021

Seven top IP tips for biotech SMEs

How smaller biotechs can best overcome pitfalls and maximise the value of their inventions Read more

16 Dec 2020

Five key insights into 2020’s drug royalty transactions

It has been a year of creative and flexible deal-making with many life sciences entities taking advantage of the revenues this kind of IP monetisation can deliver Read more

10 Nov 2020

There has never been a better time to sell or buy drug royalties, says industry veteran

IAM speaks to leading deal-maker David MacNaughtan about his new fund and the growth of this form of life sciences IP monetisation Read more

27 Aug 2020

Translational research key to realising value of university IP, says UCL biopharma chief

Dr Richard Fagan of University College London Business tells IAM about the process of turning patents for early-stage research into investable assets Read more

Patent Pools

View all
19 Nov 2020

Your guide to covid-19 vaccine stakeholders’ IP strategies

IAM examines the approaches taken by – and the issues facing – the leading companies in the race to find effective coronavirus inoculations Read more

20 Jul 2020

After success of early stage covid-19 vaccine trial, Oxford University's coronavirus IP policy explained

With the promising news today that a coronavirus vaccine being developed by scientists at the university is safe and triggers an immune response, we revisit our exclusive April interview with the head of Oxford's tech transfer office in which he talks about its new, expedited, approach to granting covid-related licences Read more

23 Jun 2020

Big Pharma facing shortage of late-stage assets as M&A dries up

Pandemic has thrown a spanner in the works for large life sciences companies, which have fewer phase three novel drugs than at any point in the last decade Read more

18 Jun 2020

Takeda offloads yet more “non-core” assets with other deals likely to follow

The Japanese big pharma continues to divest drug rights to pay down its debt and fund desperately needed innovation Read more

Patents Law

View all
19 Oct 2021

Investment in medical device IP is surging

Diagnostic innovation buyouts drive resurgence of med-tech deal-making Read more

15 Oct 2021

Moderna’s covid-19 patent pledge may be backfiring

Though a short-term PR success, the company’s commitment risks looking hollow after its decision not to license know-how to new WHO Africa tech-transfer hub Read more

7 Oct 2021

Four IP takeaways from Merck’s $11.5 billion Acceleron acquisition

Merck has struck the biggest life sciences M&A deal of 2021 so far. Here are the four key IP-related takeaways. Read more

16 Sep 2021

Apple didn’t want fair FRAND arbitration, Qualcomm VP says of epic litigation battle

Marc Snyder also claims that the iPhone giant helped the FTC craft “bizarre” antitrust claims that were eventually dismissed Read more

Strategy

View all
15 Sep 2021

Uber and Cruise band together for launch of new auto IP group

The Auto Transportation Association will bring together executives in transportation companies to communicate and collaborate on patent-related issues Read more

8 Apr 2021

Multibillion-dollar BridgeBio deal is a boost for patent-centric pharma business models

Hub-and-spokes life sciences companies are providing new opportunities for IP monetisation Read more

9 Mar 2021

Covid-19 patent landscape confusion is a big concern for life sciences organisations

Providing new insights into recent filings, but patent landscape uncertainties may pose dangers in the wake of the pandemic Read more

25 Feb 2021

What life sciences businesses need to know about data commercialisation

A strategy for protecting and exploiting data is now a must for entities involved in healthcare research Read more

Technology Licensing

View all
15 Oct 2021

Moderna’s covid-19 patent pledge may be backfiring

Though a short-term PR success, the company’s commitment risks looking hollow after its decision not to license know-how to new WHO Africa tech-transfer hub Read more

26 Aug 2021

Pfizer’s $2.3 billion spend on CD47 inhibitors shows how oncology IP continues to drive pharma deal-making

The acquisition of the cutting-edge haematology candidates is just the latest development in the booming immuno-oncology market Read more

12 Aug 2021

mRNA IP will be hot property beyond the pandemic

$3.2 billion Sanofi deal is unlikely to be the last as Big Pharma seeks to consolidate its position in the cutting-edge field Read more

5 Aug 2021

Healthcare Royalty Partners’ $750 million IPO to be next milestone for a booming market

The company is hoping to raise cash to help expand its purchasing power when acquiring pharmaceuticals revenue streams Read more

Trade Secrets

View all
15 Oct 2021

Moderna’s covid-19 patent pledge may be backfiring

Though a short-term PR success, the company’s commitment risks looking hollow after its decision not to license know-how to new WHO Africa tech-transfer hub Read more

17 Jun 2021

Everything you need to know about the covid-19 IP waiver negotiations

With text-based discussions of a TRIPS suspension about to get underway, IAM highlights the key issues to be aware of. Read more

6 May 2021

Biden backs covid-19 IP waiver in historic US policy shift

Landmark move suggests realignment in America’s domestic and international healthcare IP stance Read more

20 Apr 2021

TRIPS covid vaccine IP waiver proposal fails to address crucial questions

President Biden and other leaders are coming under pressure to agree a suspension of IP rights, but a key point has been missed Read more

Valuation

View all
19 Oct 2021

Investment in medical device IP is surging

Diagnostic innovation buyouts drive resurgence of med-tech deal-making Read more

7 Oct 2021

Four IP takeaways from Merck’s $11.5 billion Acceleron acquisition

Merck has struck the biggest life sciences M&A deal of 2021 so far. Here are the four key IP-related takeaways. Read more

26 Aug 2021

Pfizer’s $2.3 billion spend on CD47 inhibitors shows how oncology IP continues to drive pharma deal-making

The acquisition of the cutting-edge haematology candidates is just the latest development in the booming immuno-oncology market Read more

12 Aug 2021

mRNA IP will be hot property beyond the pandemic

$3.2 billion Sanofi deal is unlikely to be the last as Big Pharma seeks to consolidate its position in the cutting-edge field Read more